Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Randall Starling, MD, MPH, is Head of the Section of Heart Failure and Cardiac Transplant Medicine, the Medical Director of the Kaufman Center for Heart Failure and a Staff Cardiologist in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine. He also serves as Vice Chairman of Cardiovascular Medicine, Operations. He specializes in congestive heart failure, cardiac transplantation, cardiomyopathy and mechanical circulatory support devices. Dr. Starling was appointed to the Cleveland Clinic in 1995 as a Staff Physician and Director of the Heart Transplant Medical Services. He has a joint appointment as a Staff Physician in Cleveland Clinic’s Multi-Organ Transplant Center. He is board-certified as a Diplomate in internal medicine and in the subspecialty of cardiovascular disease. In addition, he is certified by the National Board of Medical Examiners.
Dr. Starling did his undergraduate work in biology, graduating cum laude from the University of Pittsburgh. He continued his education at the University of Pittsburgh School of Public Health, where he graduated summa cum laude with a Master’s Degree in Public Health. He received his medical training at Temple University where he was an Honor Graduate, was inducted into the Alpha Omega Alpha medical honor society and was awarded the Mosby Book Scholarship. He returned to the University of Pittsburgh Medical Center to complete his internship and residency in internal medicine.
During the course of his clinical training and association with the University of Pittsburgh Medical Center, Dr. Starling became Chief Medical Resident, Instructor in Medicine and Medical Director of the cardiac transplant program. Dr. Starling completed a fellowship in cardiology from the Ohio State University (OSU). During the course of his association with OSU, Dr. Starling became an Associate Professor of Medicine and Medical Director of the OSU Cardiac Transplant Program.
Dr Starling has been a principal or co-principal investigator on numerous clinical trials, including National Institutes of Health (NIH) grant-funded trials and numerous industry-sponsored trials. He conducted many other research trials including multicenter, randomized trials related to cardiac transplantation and heart failure. He has particular interest in devices and other forms of surgical therapy for heart failure.
He has published articles in a broad spectrum of scientific and professional journals and authored numerous chapters in medical textbooks. He sits on the Editorial Board of the Journal of the American College of Cardiology. Dr. Starling is a reviewer and editorial consultant for numerous other journals. He is Editor of the chapter on Heart Failure in the American College of Cardiology Self Assessment Program (ACCSAP VI). He has served as an editorial consultant on ABC’s “20/20,” CNN’s “Heroes in Medicine” and several PBS televised programs. He was named to Best Doctors in America in 2002, 2003-2004, and 2005-2007 editions.
Dr. Starling is a Fellow in the American College of Cardiology and a member of the American Heart Association Council on Clinical Cardiology, the American Society of Transplantation, the Heart Failure Society of America and the International Society for Heart and Lung Transplantation, where he serves on the Board of Directors and is Program Chair for the 2009 meeting.
Cardiomyopathy, heart failure, heart transplantation, ventricular assist device
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 6/21/2014, Dr. Starling has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Charity. Dr. Starling has consulted for the following companies but instructed them to donate all compensation directly to one or more non-profit organizations:
- Medtronic, Inc.
- Novartis International, AG
- Thoratec Corporation
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.